SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK.X is trending due to the launch of Cocky Wings LLC, a real-world business selling chicken wings, which aims to drive revenue for token buybacks. The community is excited about the potential of a meme coin with real-world utility, with many highlighting the connection to the Cardano chain ($ADA.X).

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential price targets and its role in the Real World Asset (RWA) narrative. The recent partnership with the U.S. Department of Commerce to provide economic data on-chain has generated excitement, with many believing this could signal further adoption by governments and institutions.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as its community rallies around its fair launch and Bitcoin-native nature, contrasting it with other meme coins. Community members are actively discussing its potential to outperform Dogecoin and its strong connection to the Bitcoin network. There's also excitement surrounding potential exchange listings and the involvement of C2 Blockchain.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as traders discuss its potential as a hedge against market downturns and a way to profit from an expected decrease in the Dow Jones. The community highlights its appeal as a Bitcoin-native memecoin with a fair launch and strong community support. Some traders are comparing it to Dogecoin ($DOGE) and touting its potential to "flip" DOGE, while others are considering it for downside protection amid economic uncertainty.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a deal to sell land for up to $28.74M, potentially increasing its NAV to $14.83 per share. The community is discussing the stock's low float, potential for a short squeeze, and possible breakout towards the $20-$25 range, with some comparing it to other recent low-float runners.

YUPFUN is a Solana-based meme and DeFi project that fuses viral meme culture with real decentralized finance utility. It aims to create a fun, community-driven ecosystem where users can trade, stake, and bridge tokens seamlessly across multiple liquidity pools and decentralized exchanges (DEXs) like BitStorage.finance Raydium, Orca, Meteora, PumpSwap, MintMe.com. YUPFUN isn't just about memes — it's about empowering the community with real ownership through fair launch mechanics, liquidity incentives, and cross-chain accessibility. The project also promotes creative engagement by encouraging users to create and share memes, art, and participate in community-driven events to grow the YUPFUN brand. With no VC backing, no private sales, and no hidden agendas, YUPFUN represents a true decentralized, permissionless movement blending entertainment with real blockchain functionality.

YUPFUN Token

YUPFUN.X is trending as social media buzz highlights the project's unique qualities and potential for virality. Community members are expressing strong bullish sentiment, citing positive chart indicators. The overall tone suggests excitement about YUPFUN's potential impact.

This isn’t just another token. $RISK is a symbol, a call to the fearless, the dream-chasers, the ones who know that greatness only comes to those who are willing to leap.  Born from the legendary phrase “risk it for the biscuit,” $RISK is a tribute to boldness. It’s made for those who refuse to settle, who thrive on high-stakes moments, and who would rather go all in than live with the regret of playing it safe.  In the world of $RISK, there are no participation trophies. You either take the shot or you miss the opportunity.  This token represents a lifestyle, the mindset that: 	•	Playing it safe never made legends. 	•	Caution doesn’t make history. 	•	Only the bold get rewarded.

ItForTheBiscuit

ItForTheBiscuit (RISK.X) is trending amid community excitement surrounding its team and recent technical breakouts. Discussions highlight strong community conviction and potential for further growth, with some focusing on chart patterns suggesting positive momentum. The project's fundamentals and its potential within the broader meme coin landscape are also being actively discussed.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending following positive Phase 2 trial data for their uveal melanoma treatment, darovasertib, and crizotinib combination, as well as a successful FDA meeting regarding accelerated approval. The community is discussing the potential for this therapy to transform cancer care and address unmet medical needs, especially given upcoming catalysts and clinical data updates. Analysts are also weighing in with price target increases.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as chatter increases around a potential licensing deal with AstraZeneca and positive trial data, sparking community speculation about an imminent catalyst. The community is actively debating the significance of recent developments and whether they will lead to a substantial rise. Bullish investors are pointing to insider buying and strong analyst ratings, while others remain cautious, awaiting further confirmation.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam (ALNY) is trending amid discussions around potential catalysts from pipeline readouts and a recent collaboration with Roche. Community members are analyzing wave structures and identifying potential buying opportunities based on technical analysis. Bullish sentiment is driven by growth expectations for Amvuttra and Alnylam's RNAi platform, though some express valuation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare Inc. (IXHL) on Tuesday announced positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The stock shot up nearly 15% in Tuesday’s pre-market session.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-reports-positive-results-phase-2-clinical-trial-psx-001">said</a> that the results from the trial confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, including on the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group. This difference was statistically significant and sustained across the 11-week follow-up period, the company said.Of patients receiving treatment, 27% achieved full disease remission, five times higher than placebo. Quality of life also improved by an average of 10.6 points on the Personal Wellbeing Index in the PSX-001 group versus 2.7 points for placebo. “Psi-GAD demonstrated a reduction in anxiety, improved mood, enhanced quality of life, and better day-to-day functioning. Importantly, the treatment effect was durable and observed across 11 weeks,” said Lou Barbato, Chief Medical Officer of Incannex.The company is now preparing to initiate a multi-jurisdiction mid-stage clinical trial. Incannex is also exploring strategic partnerships to accelerate development and broaden global access to PSX-001.Treatment with Psi-GAD was well tolerated across the study population, the company said. The majority of treatment-emergent adverse events (TEAEs) were transient, mild to moderate in nature, and consistent with the expected pharmacological effects of Psilocybin, the company said. It added that there were no signs of concerns often cited with psychedelic treatments, such as increased suicidality, psychosis, or prolonged psychological distress. However, one subject withdrew from the trial, Incannex said.&nbsp;IXHL stock is down by 65% this year and by 61% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-oral-drug-delivers-significant-weight-loss-in-late-stage-study/chsHtgtRdj7">Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Why Is Incannex Healthcare Stock Surging Today? 

The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.

Equity

The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.


Incannex Healthcare Inc. (IXHL) announced on Friday that its board of directors has authorized a share repurchase program for up to $20 million of the company’s outstanding shares of common stockShares of the company were up 23% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:573/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_11_04_37_AM_png_83c7c67ea2.webp" alt="IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="573" height="60"><figcaption>IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes that the stock will trade over $1 soon.<stembedurl>https://stocktwits.com/Uppy/message/626218079</stembedurl>The company said that it may repurchase shares of common stock through open market purchases, privately negotiated transactions, accelerated share repurchase arrangements, or other methods. The timing and amount of any repurchases will depend on market conditions, available capital resources, among other factors, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-healthcare-authorizes-20-million-share-repurchase">added</a>.CEO Joel Latham said that the firm believes the current market valuation does not accurately reflect the significant progress it has made across its clinical programs. “This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders,” he added.Incannex has three clinical-stage product candidates. Its lead candidate, IHL-42X, an oral fixed-dose combination of Dronabinol and Acetazolamide, is designed for the treatment of obstructive sleep apnea. The other programs are in development for rheumatoid arthritis and generalized anxiety disorder.In July, the company said that it is well-positioned to advance its portfolio of drug candidates through the next stages of development with a cash balance of about $50 million.IXHL stock is down by 73% this year and by 68% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/macquarie-downgrades-li-auto-on-rising-competition-in-chinese-market/chsZ3xRRdKb">This Stock Just Got Downgraded By Macquarie On Rising Competition In Chinese Market – Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

The company’s CEO said that the current market valuation does not accurately reflect the significant progress the firm has made across its clinical programs.

Shares of Incannex Healthcare Inc. hit their highest levels in nearly two months on Wednesday after the company released updates about its lead candidate, IHL-42X, a once-daily oral treatment for obstructive sleep apnea (OSA).The company announced completion of patient dosing for the Phase 2 portion of the RePOSA Phase 2/3 trial on May 8 and expects to finish final follow-up assessments by May 17.&nbsp;Shares of Incannex surged 720% on May 14 to close at $0.70, with the stock rising another 24% to $0.87 in after-hours trading.The program's pharmacokinetic and safety profiles, and clinical knowledge will help progress upcoming development stages and regulatory discussions with the FDA.The FDA end-of-Phase II meeting will formulate regulatory approaches for a new drug application.The company started its Phase 3 preparations, which will enroll 440 patients across multiple U.S. trial sites. U.S. investigators and trial participants drove the decision to concentrate geographically.IHL-42X treats intermittent hypoxia, defined by repeated blood oxygen level decreases, and hypercapnia, which involves carbon dioxide accumulation in the blood from inadequate airflow during sleep.Patients receive a dual therapy of dronabinol and acetazolamide to achieve combined effects that lessen disease severity.The Australian Phase 2 trials revealed that the lowest dose achieved a 51% reduction in the Apnea-Hypopnea Index (AHI) on average.&nbsp;Subsequent studies reported progress in measuring hypoxic burden (HB), which shows a stronger link to cardiovascular outcomes compared to AHI measurements.The company pointed out that IHL-42X may be used as a broader treatment option than weight loss therapies because data reveals that 67% of OSA patients are not obese.&nbsp;It also announced initiation of early commercial engagement initiatives, which demonstrate increasing attention from prospective partners.&nbsp;Incannex has advanced multiple late-stage drug candidates, including IHL-675A targeting inflammatory conditions and PSX-001 for generalized anxiety disorder.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested the sharp move in Incannex was part of what they described as a broader wave of "penny bio pharma mania" unfolding in the market.<stembedurl>https://stocktwits.com/StockFlips/message/614689194</stembedurl>Meanwhile, another user expressed regret over missing the rally while driving and hoped the stock would climb again the next day.<stembedurl>https://stocktwits.com/Moodymoney/message/614690960</stembedurl>The stock has declined 65.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Surges 720% On Sleep Apnea Trial Progress: ‘Penny Bio Pharma Mania’ Lifts Retail Sentiment

The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.

Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.
read more...

FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug...

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Up 113.1% in March

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety

 Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Clarion Clinics Open for Psychedelic-Assisted Treatments

Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.

Current Price	$0.525
Prev Close	$0.58
Open	$0.5596
Dividend Yield	0.00%
50-Day Moving Average	$0.5179
Beta	0.00
Avg. Volume	144.09M
PE Ratio	-0.42

52-Week High	$3.12
52-Week Low	$0.08
Market Capitalization	$49.19M
EPS (Annual)	-$1.14
Price to Book	1.26
Revenue Per Employee	$1,333.33
Enterprise Value/EBITDA	N/A

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News

IXHL Incannex Healthcare Limited - ADR